Company Overview
IMNM Clinical-stage biotech focused on targeted cancer therapies, especially antibody–drug conjugates (ADCs) and precision oncology.
Lead Asset — Varegacestat (desmoid tumors)
Phase 3 RINGSIDE: 84% reduction in risk of progression; 56% response rate → compelling best-in-class profile.
Regulatory path: NDA planned Q2 2026, setting up the company’s first commercial launch and a major inflection point.
Pipeline Momentum (2026–2027 catalysts)
IM-1021 (ROR1 ADC): early Phase 1 data in 2026.
IM-3050 (FAP radioligand): entering Phase 1.
Multiple preclinical ADCs → INDs, broadening optionality across hard-to-treat tumors.
Why It Matters
Differentiated targets + next-gen payloads → partnerability and durable competitive moat.
Multi-asset pipeline = layered catalyst stack through 2026–2027.
Investment View
Bullish above: $21–$22
Upside target: $40–$42 — driven by NDA/launch setup and ADCs + radioligand pipeline execution.
IMNM Clinical-stage biotech focused on targeted cancer therapies, especially antibody–drug conjugates (ADCs) and precision oncology.Lead Asset — Varegacestat (desmoid tumors)
Phase 3 RINGSIDE: 84% reduction in risk of progression; 56% response rate → compelling best-in-class profile.
Regulatory path: NDA planned Q2 2026, setting up the company’s first commercial launch and a major inflection point.
Pipeline Momentum (2026–2027 catalysts)
IM-1021 (ROR1 ADC): early Phase 1 data in 2026.
IM-3050 (FAP radioligand): entering Phase 1.
Multiple preclinical ADCs → INDs, broadening optionality across hard-to-treat tumors.
Why It Matters
Differentiated targets + next-gen payloads → partnerability and durable competitive moat.
Multi-asset pipeline = layered catalyst stack through 2026–2027.
Investment View
Bullish above: $21–$22
Upside target: $40–$42 — driven by NDA/launch setup and ADCs + radioligand pipeline execution.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.